

DSM Pharmaceutical Products

45 Waterview Blvd
Parsippany, NJ 07054-1298

DSM Pharmaceuticals Inc. Announces Expanded Service Offering for Solid Dose Formulation Development and CTM Manufacturing

(Parsippany – November 6, 2007)

DSM Pharmaceuticals Inc., a leading global supplier of pharmaceutical manufacturing services, announces today that they have expanded their service offerings to include Formulation Development and Clinical Trial Manufacturing for solid dosage form products.

Averaging over 20 product launches per year, DSM has a 37 year history of successfully manufacturing complex solid dosage forms for the commercial pharmaceutical market. “This expansion of services will have significant value-added benefits to our customers in terms of reducing cost and accelerating time to market as they will be able to avoid the high cost of tech transfers required for commercial launch by conducting development, CTM and commercial manufacturing all at DSM’s Greenville, NC facilities,” said Terry Novak, President and Business Unit Director of DSM Pharmaceuticals, Inc.

DSM Pharmaceutical Development Services will include:

- Preformulation
- Analytical Development
- Stability studies
- Formulation Development
 - NCE formulation development
 - Reformulations for line extensions
 - Controlled and Modified release
 - Controlled Substances
- Clinical Trial Supply – Phase I-III
- Regulatory Support

About DSM Pharmaceuticals Inc.

DSM Pharmaceuticals, Inc. a business unit of DSM Pharmaceutical Products, is a global provider of custom manufacturing services to the pharmaceutical and biopharmaceutical industries. Our breadth of manufacturing services include the areas of steriles, orals and topicals, including dose form manufacturing, scheduled drugs, clinical manufacturing, fill finish manufacturing, and lyophilization services.

About DSM Pharmaceutical Products

DSM Pharmaceutical Products is a global provider of high quality custom contract manufacturing services to the pharmaceutical and biopharmaceutical industries. DSM Pharmaceutical Products provides contract manufacturing services including: advanced intermediates, active ingredients (API's), amino acids and derivatives, mammalian cell culture production (fed-batch and perfusion) of monoclonal

antibodies, proteins, vaccines, finished dose manufacturing of solid dose, scheduled drugs, liquids, aseptic liquid and lyophilized products.

From clinical to commercial services, DSM focuses the right resources on providing the highest level of service and quality while applying innovative solutions to satisfy customers' unique manufacturing and development needs.

About DSM

DSM creates innovative products and services in Life Sciences and Materials Sciences, contributing to the quality of life. DSM's products and services are used globally in a wide range of markets and applications, supporting a healthier, more sustainable and enjoyable way of living. End markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrics & electronics, life protection and housing. The company strategy, [Vision 2010 – Building on Strengths](#), focuses on accelerating profitable and innovative growth of the company's specialties portfolio. The key drivers of this strategy are market-driven growth and innovation, an increased presence in emerging economies and operational excellence. DSM has annual sales of almost EUR 9 billion and employs some 22,000 people worldwide. The company is headquartered in the Netherlands, with [locations](#) in Europe, Asia, the Americas, Africa and Australia. More information on DSM can be found at www.dsm.com.

Forward-looking statement

This press release contains forward-looking statements. These statements are based on current expectations, estimates and projections of DSM management and information currently available to the company. The statements involve certain risks and uncertainties that are difficult to predict and therefore DSM does not guarantee that its expectations will be realized. Furthermore, DSM has no obligation to update the statements contained in this press release.

For more information:

DSM Pharmaceutical Products

Terry Novak

President

Business Unit Director

DSM Pharmaceuticals Inc.

+1-973-257-8471

Terry.Novak@dsm.com